

## rivaroxaban 2.5mg film-coated tablet (Xarelto®)

Bayer Plc Ltd

### In confidence

11 January 2019

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows:

**ADVICE:** following a full submission

**rivaroxaban (Xarelto®)** is accepted for restricted use within NHSScotland.

**Indication under review:** Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with:

- coronary artery disease, or
  - symptomatic peripheral artery disease
- at high risk of ischaemic events.

**SMC restriction:** use in patients with stable coronary artery disease that does not require dual antiplatelet therapy.

Addition of rivaroxaban to low-dose aspirin (acetylsalicylic acid) reduced the incidence of a composite outcome that included stroke, cardiovascular death and myocardial infarction, mainly due to reductions in stroke and cardiovascular death. It also increased the incidence of major bleeding.

Advice must be treated in strict confidence until published on the [SMC website](#) on **Monday 11 February 2019**.

**Chairman**  
**Scottish Medicines Consortium**